One of the hot topics at the recently concluded AIDS 2022 conference held in Montreal, Canada, was how HIV prevention interventions such as pills or injections that prevent HIV infection should be made available to different groups of people. Tiyese Jeranji spoke to some local experts and an activist about the rich set of discussions.
The world stands at an inflection point once more in the war against HIV. For those of us working in the field in South Africa, especially, it feels eerily like the battle that was fought 25 years ago, writes Dr Liesl Page-Shipp.
In 2021, HIV was successfully suppressed in the bodies of around 63% of the close to eight million people living with HIV in South Africa. This is according to recent outputs from Thembisa, the leading mathematical model of HIV in South Africa. With the help of some graphs, Spotlight editor Marcus Low unpacks this and other key model outputs.
The National Department of Health says that lubricant should be freely available alongside condoms at clinics around the country. But according to community-led monitoring group Ritshidze, clinics often do not offer lubricant. Biénne Huisman reports on why access to lubricant is important for HIV prevention and why oil-based lubricants should not be used with condoms.
The South African Health Products Regulatory Authority recently approved the use of the monthly dapivirine vaginal ring for women 18 years and older to reduce the risk of HIV infection. Thabo Molelekwa looks at the evidence for the ring’s efficacy and asks what plans there are for making it available to women in South Africa.
Broadly neutralising antibodies (bnAbs) are one of the most active and exciting areas in HIV research. Last year Spotlight reported on a “proof of concept” study showing that a specific bnAb can successfully prevent infection with certain strains of HIV. Now, we also have intriguing findings suggesting that bnAbs may have a role to play in the treatment of HIV in children. Elri Voigt reports.
Even though the rate of new HIV infections in young women and adolescent girls remains stubbornly high, provision and uptake of pills that can prevent HIV infection have generally been slow and lagging. One potential solution presented at the recent Conference on Retroviruses and Opportunistic Infections is to provide the pills at schools. Tiyese Jeranji reports.
An HIV prevention injection taken every two months was recently approved in the United States. Several HIV activists interviewed by Thabo Molelekwa say that access to the injection should be prioritised in South Africa and that we need to do a better job in rolling out the injection than we did with the rollout of prevention pills.
There is no time to waste in planning the South African rollout of cabotegravir (CAB LA), the long-lasting antiretroviral injection approved for use in the United States in December 2021, say local health experts.
A new study has analysed the change in the rate of new HIV infections from 2010 to 2019 and found that HIV incidence in South Africa has halved since 2010. This is mainly due to antiretroviral treatment and condom promotion, but male medical circumcision and behaviour change after HIV diagnosis had a role too, writes Leigh Johnson.
On World AIDS Day, Dr Thembisile Xulu, CEO of the South African AIDS Council will share a podium with Deputy President David Mabuza for the country’s official commemoration event in Limpopo. Bienne Huisman spoke to her about how she settled into the CEO role and what keeps her busy.
The top priority in our HIV programme should be to make it as easy as possible for people to start and stay on treatment. Yet, as a number of provincial reports released this year by community monitoring group Ritshidze have shown, there are many healthcare system factors that work directly against this objective. Spotlight editor Marcus Low considers some of the potential solutions.
